ANN ARBOR — The endocrine drug developer Millendo Therpeutics Inc. this week announced the appointment of three new vice presidents.
They are:
* John Kirk as vice president of regulatory affairs
* Naidong Ye. as vice president of chemistry, manufacturing and controls
* Jennifer Minai-Azary as vice president of finance.
Kirk will be responsible for the development and implementation of the company’s regulatory strategies including submissions, quality and registrations, and joins Millendo from Amicus Therapeutics.
Ye will assume management and leadership of all CMC-related activities, including pharmaceutical manufacturing and product development, and joins Millendo from AstraZeneca Pharmaceuticals.
Minai-Azary was previously senior director of finance and administration at Millendo; in her new role, she will be responsible for the company’s finance functions, including controllership and treasury.
“John, Naidong and Jen are highly skilled and motivated individuals who will provide significant value to our organization as we continue to build our portfolio of potentially first-in-class product candidates for endocrine diseases,” said Julia C. Owens, president and CEO of Millendo. “Their collective expertise will be instrumental to the advancement of our programs, and we look forward to their contributions as we progress in our mission to improve the quality of life for patients who have limited or no approved treatment options.”
Prior to his role at Amicus, Kirk sreved as executive director of regulatory affairs at Aegerion Pharmaceuticals, and held various roles at Parke-Davis and Pfizer. He has a doctorate in outcomes research from the Tulane University School of Public Health and Tropical Medicine, Department of Health Systems Management. He earned his master’s degree in chemistry and a bachelor’s degree in biological sciences from Wright State University.
Prior to AstraZeneca, Ye was chief technology officer at Dongguan Jinmeiji Pharmaceutical Co. and Guangzhou Techkeen Pharmaceutical Co., as well as working at Vela Pharmaceuticals Inc., which was purchased by Pharmos, and ViroPharma Inc. Ye holds a Ph.D. in chemistry from the Ohio State University and completed postdoctoral training at the University of Kansas. He earned his B.S. in chemistry from Zhongshan University in Guangzhou, China.
Prior to joining Millendo, Minai-Azary was director of technical accounting at Parexel International, and earlier was an accountant at Ernst & Young LLP. She holds bachelor’s and master’s degrees in accounting from the University of Michigan.
Millendo Therapeutics is developing treatments for endocrine diseases caused by hormone dysregulation. Treatments are being sought for polycystic ovary syndrome, the most common endocrine disease in women; congenital adrenal hyperplasia, a recessive genetic defect of cortisol synthesis; eEndogenous Cushing’s Syndrome, a condition resulting from chronic cortisol excess; and adrenocortical carcinoma, a rare endocrine malignancy of the adrenal cortex.
More at www.millendo.com.